Computer system validation in the perspective of the pharmaceutical industry
Abstract
Computer Systems Validation (CSV) is a process used to ensure (and document) that a computer based systems will produce information or data that meet a set of defined requirements. If a system meets these requirements, it can be assumed that it is consistently performing in the way it was intended. Quality is an imperative for customers whenever they consider a product or service. It is also important as it relates to life-saving products such as pharmaceuticals. In this regard, the Food and Drug Administration introduced good manufacturing practice (GMP) to maintain and improve the quality of pharmaceutical products. GMP ensures that products are consistently produced and controlled according to the quality standards appropriate to the intended use and as required by the marketing authorization. One of the major GMP requirements is that all of the critical manufacturing equipment, utilities, and facilities in the pharmaceutical industries must be properly qualified and validated prior to production. Currently, this practice forms the core of the regulations that are strictly followed by pharmaceutical companies worldwide. A validation assessment program is a necessity in the pharma industry to ensure adherence to pharmaceutical cGMP guidelines, and to help companies maintain consistent quality. The same principles are applied in computer system validation to a computer system or an information technology system. It’s essential to maintain quality standards in pharma since non-conformance can have far-reaching consequences. Computer system validation checks the effectiveness and the efficiency with which the system is meeting the purpose for which it was designed. This study aims to identify needs of computer system validation of instrument/equipment practiced in the perspective of pharmaceutical industry.
Keywords: Computer system validation, Validation, Qualification, GAMP
DOI
https://doi.org/10.22270/jddt.v8i6-s.2102References
Agalloco, J, Carleton FJ, Validation of Pharmaceutical Process, 3rd Edition, USA, New York: Informa Healthcare, 2008.
Sangeetha NKD, Bala krishna P, Development and validation of a UPLC method for the determination of duloxetine hydrochloride residues on pharmaceutical manufacturing equipment surfaces, Pharmaceutical Methods, 2011; 2 (3):161–166.
Giridhar A, Hamdan I, Joglekar G, Venkatasubramanian V, Reklaitis GV, Real-time process management in particulate and pharmaceutical systems, Computer Aided Chemical Engineering, 2011; 29:1035–1039.
Bedson P, Sargent M, The development and application of guidance on equipment qualification of analytical instruments, Accreditation and Quality Assurance, 1996; 1(6):265-274.
Coombes P, Laboratory Systems Validation Testing and Practice, DHI Publishing, LTD, Raleigh, USA 2002.
US Food & Drug Administration - Guidance for Industry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations, September 2006.
US Food & Drug Administration - Guidance for Industry Process Validation: General Principles and Practices – Revision 1, January 2011.
US Food & Drug Administration - General Principles of Software Validation; Final Guidance for Industry and FDA Staff, January 2002.
US Food & Drug Administration - Guidance for Industry: 21 CFR Part 11 - Electronic Records and Electronic Signatures: Scope and Application, August 2003.
PIC/S Good Practices for computerized systems in regulated “GxP” environment, Pharmaceutical Inspection Co-operation Scheme guidance, September 2007.
GAMP Forum – GAMP Guide, A Risk-Based Approach to complaint GxP Computerized Systems - Ver. 5.0
GAMP Forum – GAMP Good Practice Guide, Testing of GxP Systems.
GAMP Forum – GAMP Good Practice Guide, A Risk-Based Approach to Compliant Electronic Records and Signatures.
GAMP Forum – GAMP Good Practice Guide, Global Information Systems Control and Compliance.
GAMP Forum – GAMP Good Practice Guide, A Risk-Based Approach to Operation of GxP Computerized Systems – 2010.
FDA, “Guidance for Industry: Regulatory Submissions in Electronic Format for New Drug Application (NDA),” http://www.fda.gov/cder/guidance/2353fnl.pdf.
FDA, “Guidance for Preparing Data for Electronic ANDA Submission,” http://www.fda.gov/cder/ guidance/3223fnl.htm.
FDA, “Revised Guidance for Providing Regulatory Submissions to CBER in Electronic Format,” http://www.fda.gov/cber/gdlns/ebla.pdf.
FDA, “Enforcement Policy: 21 CFR Part 11, Electronic Records, Electronic Signatures” (CPG 7153.17, 13 May 1999), http://www.fda.gov/ ora/compliance_ref/cpg/cpggenl/cpg160-850.htm.
FDA, “Public Docket Index for 21 CFR Part 11 (E-Rec/E-Sig Rule),” http://www.fda.gov /ora/compliance_ref/Part1 1/dockets_index.htm.
FDAMA, SEC. 410, “Mutual Recognition Agreements and Global Harmonization,” http://www.fda.gov /cder/guidance/105-115.htm#SEC.
CDER Warning Letters Web site: http://www.fda.gov/foi/warning_letters/m5056n.pdf and http://www.fda.gov/foi/warning_letters/m5057n.pdf.
FDA Cyber Warning Letters Web site: http://www.fda.gov/cder/warn/cyber/cyber2017.htm.
GAMP and ISPE Web site: http://www.gamp.org and http://www.ispe.org.
PDA Web site: http://www.pda.org.
PIC Web site: http://www.picscheme.org/index.htm.
Information Society Standardization System Web site: http://www.cenorm.be/isss/
International Biometric Industry Association Web site: http://www.ibia.org.
ComputerValidation.com Web site: http://www.computervalidation.com
Published
Abstract Display: 3697 
PDF Downloads: 2442 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.